PPARA and metabolic dysfunction-associated steatohepatitis: A more recent study comparing different PPAR agonists in experimental NASH in mice, revealed that PPARδ agonism and lanifibranor (pan-PPAR agonist) directly regulate the activation of liver macrophages, synergistically modulating NASH in addition to beneficial metabolic effects of PPARα/γ agonists [146].